BOTOX® Treatment in Pediatric Upper Limb Spasticity

Allergan

Status and phase: Completed; Phase 3

Conditions: Pediatrics; Stroke; Cerebral Palsy; Muscle Spasticity

Treatments: Drug: Normal Saline (Placebo); Biological: botulinum toxin Type A

Study type: Interventional

Funder types: Industry

Identifiers

NCT01603602

191622-101

2012-000062-38 (EudraCT Number)

Details and patient eligibility

About

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.

Enrollment: 235 patients

Sex: All

Ages: 2 to 16 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Minimum weight of 10 kg/22 lb
• Upper limb spasticity due to cerebral palsy or stroke

Exclusion criteria

• Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease
• Uncontrolled epilepsy
• Botulinum Toxin therapy of any serotype for any condition within the last 6 months
• Previous surgical treatment of the study limb (except tendon lengthening), or planned surgery of the study limb during the study
• Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected lower limb during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

235 participants in 3 patient groups, including a placebo group

BOTOX® 3 U/kg

Experimental group

Description:

Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).

Treatment:

Biological: botulinum toxin Type A

BOTOX® 6 U/kg

Experimental group

Description:

Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.

Treatment:

Biological: botulinum toxin Type A

Placebo

Placebo Comparator group

Description:

Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.

Treatment:

Drug: Normal Saline (Placebo)